Biocon (BIOCON) Share Price Falls 2.22% as Stock Trades at Rs 402.25
- August 31, 2026
- Posted by: Harsh Piplani
- Category: News
Biocon Share Price fell today as the stock closed at Rs 402.25, down 2.22% from the previous close of Rs 411.4. The company’s market capitalisation stood at Rs 67,045.62 crore, placing it in the Large Cap category. This Biocon Share Price move is relevant because it occurred during a session with a clear intraday range and without any company-specific catalyst supplied in the data. Biocon Stock News today therefore centres on verified price action, valuation context and the broader healthcare comparison set tracked by Univest.
The decline puts Biocon Share Price Today in focus for investors monitoring stock market news, market cap context and the company’s relative standing in the Pharmaceuticals & Drugs industry. The supplied data confirms the price event, but it does not establish a company-specific reason for the fall. In that setting, the most useful reading is to examine the day’s range, turnover, valuation multiples and peer benchmarks before drawing conclusions. Univest uses the same factual approach in its live stock coverage and stock analysis pages.
Biocon (BIOCON) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 402.25 |
| Previous Close | Rs 411.4 |
| Today's Move | -Rs 9.15 (-2.22%) |
| Open | Rs 409.95 |
| High | Rs 412.1 |
| Low | Rs 402.1 |
| Turnover | Rs 29.39 crore |
| Market Capitalisation | Rs 67,045.62 crore |
| Market Cap Category | Large Cap |
Biocon Share Price Today moved from a previous close of Rs 411.4 to Rs 402.25, reflecting a day change of Rs -9.15 and a decline of 2.22%. The stock opened at Rs 409.95, reached an intraday high of Rs 412.1 and a low of Rs 402.1. That means the day’s movement remained contained within a relatively narrow band around the open, while the session ended close to the day’s low. The turnover was Rs 29.39 crore.
From a market-cap perspective, Biocon is classified as a Large Cap company and its market capitalisation is Rs 67,045.62 crore. That size context helps readers place the Biocon Share Price fall within a broader institutional-grade listed company framework without assuming anything about the reason for the move. The key takeaway from today’s trade is straightforward: Biocon Share Price Today declined in a session where the opening, high and low all stayed close to one another, and the move was fully captured by the verified close-to-close change. For readers following Biocon Share Price, the day’s trade is best read as a factual price update rather than a narrative with an unverified trigger.
In the context of Biocon Stock News, the same-day decline is most useful when read alongside company size, market cap and benchmark comparisons. Investors tracking Biocon Share Price Update can use this session as the base for further stock analysis on Univest, where the live page consolidates the latest market context in one place.
Biocon (BIOCON) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 67,045.62 crore |
| P/E Ratio | 135.36x |
| P/B Ratio | 1.97x |
| ROE | 1.35% |
| ROCE | 3.26% |
| EPS | Rs 3.04 |
| Book Value Per Share | Rs 208.53 |
| Dividend Yield | 0.12% |
Biocon’s fundamentals provide important context for the day’s share price fall. The stock trades at a P/E ratio of 135.36 and a P/B ratio of 1.97, with ROE at 1.35% and ROCE at 3.26%. EPS stands at Rs 3.04, book value at Rs 208.53 and dividend yield at 0.12%. These figures show that Biocon Share Price is being evaluated against a business profile where earnings-based valuation is materially higher than the industry median, while the book value cushion is more visible than the earnings return ratios.
The market capitalisation of Rs 67,045.62 crore is large enough to keep Biocon Share Price relevant in healthcare market updates, but the valuation and profitability ratios need to be read carefully. EPS of Rs 3.04 indicates earnings attributable to each share, while book value of Rs 208.53 shows the accounting net worth behind each share. The dividend yield of 0.12% is a factual payout measure and should be read as historical/current data rather than as a forecast. On the supplied numbers alone, Biocon Share Price News today is shaped more by valuation context and profitability metrics than by any other disclosed fundamental trigger.
For Biocon Stock Analysis, the gap between P/E and peer or sector averages is especially important. Univest’s research framework places that valuation alongside profitability and capital efficiency metrics, which makes the Biocon Share Price story more complete than a simple one-day move headline.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 135.36x |
| Benchmark Median P/E | 31.21x |
| Benchmark Average P/E | 48.1x |
| Benchmark P/E Range | 3.7x to 672.45x |
| Company P/B Ratio | 1.97x |
| Benchmark Median P/B | 2.88x |
| Benchmark Average P/B | 4.19x |
| Company ROE | 1.35% |
| Benchmark Median ROE | 11.78% |
| Benchmark Average ROE | 10.68% |
| Company ROCE | 3.26% |
| Benchmark Median ROCE | 13.6% |
| Benchmark Average ROCE | 13.27% |
| Company Market Capitalisation | Rs 67,045.62 crore |
| Benchmark Median Market Cap | Rs 670.73 crore |
| Benchmark Average Market Cap | Rs 14,040.53 crore |
Biocon operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. Within the supplied same-industry benchmark set of 203 companies, Biocon’s P/E of 135.36 is above the sector median of 31.21, above the sector average of 48.1 and within a benchmark range of 3.7 to 672.45. Its P/B of 1.97 is below the sector median of 2.88 and below the average of 4.19. ROE at 1.35% sits below the sector median of 11.78%, while ROCE at 3.26% is also below the sector median of 13.6%.
The market capitalisation benchmark is equally useful. Biocon’s Rs 67,045.62 crore market cap is well above the sector median of Rs 670.73 crore and below the sector average of Rs 14,040.53 crore as supplied in the benchmark set. That makes Biocon Share Price part of a large company universe where relative valuation and operating returns matter to comparison-based readers. The sector context does not explain today’s fall, but it does show how Biocon Share Price is positioned against other Pharmaceuticals & Drugs names tracked by Univest.
For readers searching Biocon Share Price Today, this sector lens matters because the company’s earnings multiple is much higher than the industry median, while ROE and ROCE remain below the benchmark medians. Biocon News Today therefore sits at the intersection of price action and valuation comparison, not at the level of a verified event catalyst.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,60,696.31 | 38.09 | 5.33 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,46,062.83 | 84.12 | 13.93 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,91,515.22 | 87.81 | 21.34 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,18,403.7 | 26.24 | 4.39 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,14,554.33 | 33.99 | 3.26 | 11.83 | 16 |
Biocon Share Price can also be compared with selected listed peers in the same industry. Biocon’s market cap of Rs 67,045.62 crore is smaller than Sun Pharmaceutical Industries at Rs 4,60,696.31 crore, Divi’s Laboratories at Rs 2,46,062.83 crore, Torrent Pharmaceuticals at Rs 1,91,515.22 crore and Zydus Lifesciences at Rs 1,18,403.7 crore, but larger than some other peers in the broader set.
On valuation, Biocon’s P/E of 135.36 is above Sun Pharma’s 38.09, Zydus Lifesciences’ 26.24 and Cipla’s 33.99, while also above the peer figures shown for Divi’s Laboratories at 84.12 and Torrent Pharmaceuticals at 87.81. On returns, Biocon’s ROE of 1.35% and ROCE of 3.26% are below all the listed comparison names. The peer set therefore places Biocon Share Price in a more expensive earnings-multiple position than several healthcare peers, while showing weaker capital-return ratios on the supplied data.
That relative picture is important for anyone scanning Biocon Stock News or Biocon Share News on Univest. The comparison does not offer a price target or recommendation, but it does show how the Biocon Share Price Today move sits against peer valuation and profitability metrics in a highly comparable industry segment.
Why Investors Are Watching Biocon
- Biocon Share Price fell 2.22% today to Rs 402.25 after closing at Rs 411.4 in the previous session.
- The day’s price range was Rs 402.1 to Rs 412.1, with an opening price of Rs 409.95.
- Biocon’s market capitalisation is Rs 67,045.62 crore, and the company is classified as Large Cap.
- The stock trades at a P/E of 135.36, P/B of 1.97, ROE of 1.35% and ROCE of 3.26%.
- Against the supplied healthcare peer set, Biocon Share Price sits on a higher earnings multiple and lower return ratios.
About Biocon
Biocon operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied data identifies the company within a large-cap listed universe on NSE and BSE coverage tracked by Univest. In the current market context, Biocon Share Price is followed for its valuation, sector positioning and comparison with other pharmaceutical names. The company-specific facts supplied here are to its sector, industry and market data, so the most accurate company overview remains factual and concise.
For readers searching Biocon Stock News, Biocon Company News or Biocon Latest News, the verified profile points to a listed healthcare business that is measured against industry-wide valuation and return benchmarks. That makes Biocon Share Price Today relevant not just as a one-day move, but also as part of a broader stock performance watchlist on Univest.
Track Biocon Share Price on Univest
Use Biocon (BIOCON) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.
Investors can track Biocon Share Price on Univest for live price updates, market cap context, fundamental ratios, shareholding pattern, 52-week levels and market insights. Univest also presents the stock in a format designed for quick stock analysis, so readers can revisit Biocon Share Price Today alongside sector and peer comparisons.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Biocon Share Price falling today?
Ans. Biocon Share Price fell 2.22% to Rs 402.25 today. The supplied data confirms the move, but it does not establish a company-specific catalyst for the decline, so the event should be read as verified price action.
What was Biocon Share Price Today’s close?
Ans. Biocon Share Price Today closed at Rs 402.25, compared with the previous close of Rs 411.4. That equals a decline of Rs 9.15 in the session, based on the supplied market data.
What is Biocon’s market capitalisation?
Ans. Biocon’s market capitalisation is Rs 67,045.62 crore. The company is classified as Large Cap in the supplied data, which helps place today’s price move in a company-size context. The company operates in the Healthcare sector.
How do Biocon’s valuation ratios compare with the sector?
Ans. Biocon’s P/E is 135.36 and P/B is 1.97. In the same-industry benchmark, those compare with a P/E median of 31.21 and P/B median of 2.88, showing a higher earnings multiple.
What do Biocon’s profitability ratios show?
Ans. Biocon reports ROE of 1.35% and ROCE of 3.26%. Both are below the same-industry benchmark medians of 11.78% and 13.6%, which gives useful context for Biocon Share Price analysis. ROE stands at 1.35%.
How does Biocon compare with listed healthcare peers?
Ans. Biocon’s P/E of 135.36 is above peers such as Sun Pharma at 38.09, Zydus Lifesciences at 26.24 and Cipla at 33.99. Its ROE and ROCE are also lower than those comparison names.
